RIM
IBRX icon

RS Investment Management’s ImmunityBio IBRX Stock Holding History

RS Investment Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,113,237
Closed -$9.15M – 393
2016
Q1 		$9.15M Buy
1,113,237
+81,097
+8% +$764K 0.09% 243
2015
Q4 		$17.9M Buy
1,032,140
+28,350
+3% +$421K 0.16% 196
2015
Q3 		$11.5M Buy
+1,003,790
New +$21.9M 0.1% 226

Other funds holding IBRX

WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
CC
Callan Capital La Jolla, California $1.35B AUM 8.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

RS Investment Management's IBRX Position: Q2 2016 in Review

RS Investment Management sold out of ImmunityBio (IBRX) in Q2 2016, closing a stake of 1,113,237 shares — an estimated $9.15M sold.

RS Investment Management first reported a position in IBRX in Q3 2015 and held it in 3 quarters. The position peaked at $17.9M in Q4 2015. 62 funds tracked by Wall St. Rank hold IBRX as of Q2 2016.

  • RS Investment Management reported no remaining ImmunityBio position as of Q2 2016 after selling out during the quarter.
  • RS Investment Management sold 1,113,237 ImmunityBio shares in Q2 2016, an estimated $9.15M.
  • RS Investment Management first reported a position in ImmunityBio in Q3 2015 and held it in 3 quarters.
  • RS Investment Management's ImmunityBio position peaked at $17.9M in Q4 2015.
  • 62 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2016.

Based on RS Investment Management's 13F filing for Q2 2016, filed 26 Jul 2016.